Madrigal Pharmaceuticals CEO Bill Sibold doesn’t seem worried about sharing the MASH market with Novo Nordisk’s blockbuster GLP-1 drug.
In an interview with Endpoints News on Tuesday, Sibold touted the tolerability of Madrigal’s approved MASH ...
↧